| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a63e57f785780c628946c35361ae0622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6ab3479c4b9426afd09f4efec4f69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7961c1797a50c7f7c64826fb3e5f42c9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-60 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-863 |
| filingDate |
2007-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48ebc5c8ef4c5bb1795638242014cee4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2bf0dc6f396c7c567bc682a24305259a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcba8049bddc2a7baec1b3eee7030a96 |
| publicationDate |
2007-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007132052-A1 |
| titleOfInvention |
Vectors into which the c7l gene is inserted and use of said vectors in the production of vaccines and of compositions for gene therapy |
| abstract |
The recombinant vectors of the invention have an insert with the coding sequence for the C7L gene of vaccinia or of a homologous gene under the control of a promoter that permits its expression. Said vectors protect the cells in which they are expressed from the development of apoptosis. Reinsertion of the C7L gene into the NYVAC genome reverts the apoptotic phenotype of the virus, without losing its attenuation properties. The protection against apoptosis conferred by C7L makes the vectors of the invention suitable for producing live vaccines, by increasing the expression time and presentation of additional antigens encoded in its genome, or for preparing compositions for extended-term gene therapy for actuation in target cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9670506-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10370679-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010127115-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345928-B2 |
| priorityDate |
2006-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |